ReviewF1000Research2017
Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation.
Review in F1000Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients.Clinical and translational science · 2021Trial
- Patient-derived model capturing hypoxia and extracellular matrix remodelling of immunologically cold high-grade serous tumours.Nature communications · 2026Article
- HLA-AJournal of immunology research · 2026Article
- The Case of a Missing HLA-B Gene.HLA · 2025Article
- Transplant Eligible and Ineligible Elderly Patients with AML-A Genomic Approach and Next Generation Questions.Biomedicines · 2024Review
- Into the storm: the imbalance in the yin-yang immune response as the commonality of cytokine storm syndromes.Frontiers in immunology · 2024Review
- Article
- Analysis of FCGR3A-p.176Val variants in women with recurrent pregnancy loss and the association with CD16a expression and anti-HLA antibody status.Scientific reports · 2023Article
- DIALing-up the preclinical characterization of gene-modified adoptive cellular immunotherapies.Frontiers in immunology · 2023Review
- Minor histocompatibility antigens HA-8 and PANE1 in the TUNISIAN population.Molecular genetics & genomic medicine · 2022Article
- Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker.British journal of haematology · 2021Review
- The adverse events of haematopoietic stem cell transplantation are associated with gene polymorphism within human leukocyte antigen region.Scientific reports · 2021Article
- Revisit of Optimal Donor Number Estimation in the Hong Kong Bone Marrow Donor Registry.Frontiers in immunology · 2021Article
- [Chimeric antigen receptors in oncology: clinical applications and new developments].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2020Review
- The importance of MHC class II in allogeneic bone marrow transplantation and chimerism-based solid organ tolerance in a rat model.PloS one · 2020Article
- Genetic Diversity ofFrontiers in pharmacology · 2020Article
- Biomarkers for posttransplantation outcomes.Blood · 2018Review
- The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Graft-versus-host disease (GVHD) remains a significant potentially life-threatening complication of allogeneic hematopoietic cell transplantation (HCT). Since the discovery of the human leukocyte antigen (HLA) system over 50 years ago, significant advances have clarified the nature of HLA variation between transplant recipients and donors as a chief etiology of GVHD. New information on coding and non-coding gene variation and GVHD risk provides clinicians with options to consider selected mismatched donors when matched donors are not available. These advances have increased the availability of unrelated donors for patients in need of a transplant and have lowered the overall morbidity and mortality of HCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.